Fan Hui, Sun XiaoMeng, Zhang Heng, Liu Jia, Zhang PengRui, Xu Yuan, Pan QingRong, Wang Guang
Department of Endocrinology, Beijing Chaoyang Hospital, Capital Medical University , Beijing, People's Republic of China .
Diabetes Technol Ther. 2016 Mar;18(3):120-6. doi: 10.1089/dia.2015.0261. Epub 2016 Mar 7.
Fibroblast growth factor (FGF)-21 is an important regulator of glucose metabolism. In the present study, we investigated whether plasma levels of FGF-21 changed in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and assessed the effects of metformin treatment on plasma FGF-21 levels.
The plasma FGF-21 levels and the metabolic parameters of 226 patients with newly diagnosed T2DM and 100 sex- and age-matched normal glycemic tolerant (NGT) controls were measured. Seventy-four patients among of the 226 patients with T2DM were treated with metformin throughout the 12-week study period. The fasting plasma FGF-21 and high-sensitivity C-reactive protein (hs-CRP) levels were measured using enzyme-linked immunosorbent assay kits.
The patients with T2DM had significantly higher fasting plasma FGF-21 levels (302.2 pg/mL [range, 201.3-454.4 pg/mL] vs. 104.5 pg/mL [range, 71.6-185.6 pg/mL]; P < 0.00) and hs-CRP levels (2.63 ± 2.81 mg/L vs. 1.58 ± 2.16 mg/L; P < 0.00) than the NGT subjects. The fasting plasma hs-CRP and FGF-21 levels were significantly decreased in the T2DM group after metformin treatment compared with pretreatment (respectively, 2.56 ± 1.75 mg/L vs. 3.28 ± 1.89 mg/L [P < 0.05] and 232.6 pg/mL [range, 154.3-307.8 pg/mL] vs. 313.9 pg/mL [range, 227.7-474.2 pg/mL] [P < 0.01]).
In patients with T2DM, the plasma FGF-21 levels are increased but are significantly decreased after metformin treatment. Metformin may play a role in reducing the FGF-21 levels in patients with T2DM, likely through the amelioration of glucose-lipid metabolism and inflammation.
成纤维细胞生长因子（FGF）-21是葡萄糖代谢的重要调节因子。在本研究中，我们调查了新诊断的2型糖尿病（T2DM）患者血浆FGF-21水平是否发生变化，并评估了二甲双胍治疗对血浆FGF-21水平的影响。
测量了226例新诊断的T2DM患者和100例年龄和性别匹配的血糖正常耐受（NGT）对照者的血浆FGF-21水平和代谢参数。在为期12周的研究期间，226例T2DM患者中的74例接受了二甲双胍治疗。使用酶联免疫吸附测定试剂盒测量空腹血浆FGF-21和高敏C反应蛋白（hs-CRP）水平。
T2DM患者的空腹血浆FGF-21水平（302.2 pg/mL[范围，201.3 - 454.4 pg/mL]对104.5 pg/mL[范围，71.6 - 185.6 pg/mL]；P < 0.00）和hs-CRP水平（2.63 ± 2.81 mg/L对1.58 ± 2.16 mg/L；P < 0.00）显著高于NGT受试者。与治疗前相比，二甲双胍治疗后T2DM组的空腹血浆hs-CRP和FGF-21水平显著降低（分别为2.56 ± 1.75 mg/L对3.28 ± 1.89 mg/L[P < 0.05]和232.6 pg/mL[范围，154.3 - 307.8 pg/mL]对313.9 pg/mL[范围，227.7 - 474.2 pg/mL][P < 0.01]）。
在T2DM患者中，血浆FGF-21水平升高，但二甲双胍治疗后显著降低。二甲双胍可能通过改善糖脂代谢和炎症反应，在降低T2DM患者FGF-21水平中发挥作用。
